Neuromodulation Devices Global Market estimated to be worth $9,569.4 million by 2029

The report covers business intelligence information such as reimbursement scenario, funding scenario, clinical trials,major company's product and application matrix, overall & individual market share analysis of SCS and DBS global market.
By: IQ4I Research
BOSTON - Sept. 23, 2022 - PRLog -- The Neuromodulation devices global market report covers four segments namely product, application, end-users, and geography.

1)    Neuromodulation Devices Global Market, Based on Product:

Ø  Invasive Neuromodulation Devises
§  Spinal Cord Stimulation (SCS)
§  Deep Brain Stimulation (DBS)
§  Sacral Nerve Stimulation (SNS)
§  Vagus Nerve Stimulation (VNS)
§  Hypoglossal Nerve Stimulation (HGNS)
§  Others
o   Gastric Electrical Stimulation (GES)
o   Respiratory Electrical Nerve Stimulation (RES)/Phrenic Nerve Stimulation (PNS)

Ø  Non-invasive Neuromodulation Devices
§  Transcutaneous Electrical Nerve Stimulation (TENS)
§  Neuromuscular Electrical Nerve Stimulation (NMES)
§  Others

2)    Neuromodulation Devices Global Market, Based on Application:
Ø  Pain Management
§  Chronic Pain

§  Failed Back Surgery Syndrome (FBSS)
§  Others
Ø  Central Nervous System
§  Parkinson 's disease
§  Dystonia
§  Epilepsy
§  Others
Ø  Gastroenterology and Urology
§  Gastroparesis
§  Urinary Incontinence
§  Faecal Incontinence
Ø  Obstructive Sleep Apnea (OSA)
Ø  Other Applications
§  Obesity
§  Heart Failure
§  Autoimmune Diseases (Rheumatoid Arthritis, Multiple Sclerosis)
§  Respiratory Related Diseases (Diaphragm Pacing)
§  Diabetes
§  Weaning

3)    Neuromodulation Devices Global Market, Based on End-User:

Ø  Hospitals and Ambulatory Surgery Centers
Ø  Clinics and Physiotherapy centers
Ø  Others

4)    Nuclear Medicine Global Market, Based on Geography:

Ø  North America
Ø  Europe
Ø  Asia-Pacific
Ø  Rest of the World

According to IQ4I Research, the nuclear medicine global market is estimated to grow at a high single-digit CAGR from 2022 to 2029 to reach $9,569.4 million by 2029. Persistently increasing geriatric population, increasing incidence of chronic pain, Parkinson's and Alzheimer's disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, expansion in emerging markets, rise in the number of clinical studies performed, minimally invasive procedure, are some of the factors which are propelling the neuromodulation devices market growth.

The top players in the market are Abbott Laboratories (U.S.), Axonics Modulation Technologies, Inc. (U.S.), Bioventus (Bioness Inc.) (U.S.), Boston Scientific Corporation (U.S.), Inspire Medical Technologies (U.S.), Laborie Medical Technologies, Inc. (Canada), LivaNova Plc (U.K.),  Medtronic Plc (Ireland), Neuropace Inc. (U.S.) and Nevro Corporation (U.S.).

For more details please visit our website or contact:

Mr. Satish Birudukota,


Report link:


Phone: +91-9886722024, 8147030229

Mr. Satish Birudukota
Posted By:*** Email Verified
Tags:IQ4I Research
Location:Boston - Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
IQ4I Research & Consultancy PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share